ROCKVILLE, Md., April 29 /PRNewswire-FirstCall/ -- Vanda
Pharmaceuticals Inc. (NASDAQ:VNDA), a biopharmaceutical company
focused on the development and commercialization of clinical-stage
product candidates for central nervous system disorders, today
announced financial and operational results for the first quarter
ended March 31, 2009. Vanda reported a net loss of $6.5 million for
the first quarter of 2009, compared to $7.5 million for the fourth
quarter of 2008. Total expenses for the first quarter of 2009 were
$6.6 million, compared to $7.7 million for the fourth quarter of
2008. Research and development (R&D) expenses for the first
quarter of 2009 were $2.3 million, compared to $3.6 million for the
fourth quarter of 2008. The decrease in R&D expenses in the
first quarter of 2009 relative to the fourth quarter of 2008 is
primarily due to the decrease in regulatory consulting and other
professional fees. As of March 31, 2009, Vanda's cash, cash
equivalents, and marketable securities totaled approximately $42.6
million. As of March 31, 2009, a total of approximately 26.7
million shares of Vanda common stock were outstanding. Net loss per
common share for the first quarter of 2009 was $0.24, compared to
$0.28 for the fourth quarter of 2008. OPERATIONAL HIGHLIGHTS On
November 6, 2008, Vanda submitted a Complete Response to the not
approvable action letter that the Company received from the U.S.
Food and Drug Administration (FDA) on July 25, 2008 regarding
iloperidone. The FDA accepted the Complete Response for review and
has set a new target action date of May 6, 2009. Pending a response
from the FDA, Vanda is concentrating its efforts on the design and
evaluation of clinical development options for tasimelteon, its
compound for sleep and mood disorders, including Circadian Rhythm
Sleep Disorders. FINANCIAL DETAILS * Operating Expenses. First
quarter 2009 R&D expenses of $2.3 million, consisted primarily
of $0.5 million of salaries and benefits and $0.2 million of
non-cash stock based compensation costs for R&D personnel, as
well as $0.8 million of regulatory consultant fees, and $0.2
million of pre-clinical work. This compares to $3.6 million for the
fourth quarter of 2008 and $11.1 million for the first quarter of
2008. The decrease in R&D expenses in the first quarter of 2009
relative to the fourth quarter of 2008 is primarily due to the
decrease in regulatory consulting and other professional fees
related to iloperidone. The decrease in R&D expenses in the
first quarter of 2009 relative to the first quarter of 2008 is
primarily due to the completion in the second quarter of 2008 of
the Phase III clinical trial for tasimelteon in chronic primary
insomnia. General and administrative (G&A) expenses of $4.2
million for the first quarter of 2009 consisted primarily of $0.5
million of salaries and benefits and $2.1 million of non-cash stock
based compensation costs for G&A personnel, as well as $0.7
million of legal fees, and $0.2 million of insurance costs. This
compares to $4.1 million for the fourth quarter of 2008 and $9.0
million for the first quarter of 2008. The increase in G&A
expenses in the first quarter of 2009 relative to the fourth
quarter of 2008 is primarily due to an increase in legal and
professional fees offset by a decrease in stock-based compensation
costs. The decrease in G&A expenses in the first quarter of
2009 relative to the first quarter of 2008 is primarily due to
lower stock-based compensation and commercial expenses. Employee
stock-based compensation expense recorded in the first quarter of
2009 totaled $2.3 million. Of these non-cash charges, $0.2 million
was recorded as R&D expense and $2.1 million was recorded as
G&A expense. For the fourth quarter of 2008 and the first
quarter of 2008, total stock-based compensation expense was $0.7
million and $5.1 million, respectively. The increase in stock-
based compensation expense in the first quarter of 2009 relative to
the fourth quarter of 2008 is the result of the fourth quarter
expense encompassing the net effect of stock-based compensation for
the period for existing employees, reduced by the reversal of
stock- based compensation charges resulting from the cancellation
of unvested options in connection with the workforce reduction
which occurred in the fourth quarter of 2008. The decrease in
stock-based compensation expense in the first quarter of 2009
relative to the first quarter of 2008 is primarily due to no
options being granted in the first quarter of 2009. * Cash and
marketable securities decreased by $3.8 million during the first
quarter of 2009. Changes included $6.5 million of net losses offset
by increases in accrued expenses and accounts payable of $0.1
million, decreases in prepaid expenses of $0.2 million and $2.4
million in non-cash depreciation, amortization, and stock-based
compensation expense. * Vanda's cash, cash equivalents and
marketable securities as of March 31, 2009 totaled approximately
$42.6 million, compared to approximately $46.5 million as of
December 31, 2008. * Net loss for the first quarter of 2009 was
$6.5 million, compared to a net loss of $7.5 million for the fourth
quarter of 2008 and a net loss of $19.2 million for the first
quarter of 2008. * Net loss per common share for the first quarter
of 2009 was $0.24, compared to $0.28 for the fourth quarter of 2008
and $0.72 for the first quarter of 2008. FINANCIAL GUIDANCE Vanda
will update its financial guidance following the decision by the
FDA regarding the New Drug Application for iloperidone. ABOUT VANDA
PHARMACEUTICALS INC.: Vanda Pharmaceuticals Inc. is a
biopharmaceutical company focused on the development and
commercialization of clinical-stage product candidates for central
nervous system disorders. For more on Vanda Pharmaceuticals Inc.,
please visit http://www.vandapharma.com/. CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTS Various statements in this release are
"forward-looking statements" under the securities laws. Words such
as, but not limited to, "believe," "expect," "anticipate,"
"estimate," "intend," "plan," "targets," "likely," "will," "would,"
and "could," and similar expressions or words, identify
forward-looking statements. Forward-looking statements are based
upon current expectations that involve risks, changes in
circumstances, assumptions and uncertainties. Vanda is at an early
stage of development and may not ever have any products that
generate significant revenue. Important factors that could cause
actual results to differ materially from those reflected in the
company's forward-looking statements include, among others: delays
in the completion of Vanda's clinical trials; a failure of Vanda's
product candidates to be demonstrably safe and effective; Vanda's
failure to obtain regulatory approval for its products or to comply
with ongoing regulatory requirements; a lack of acceptance of
Vanda's product candidates in the marketplace, or a failure to
become or remain profitable; Vanda's inability to obtain the
capital necessary to fund its research and development activities;
Vanda's failure to identify or obtain rights to new product
candidates; Vanda's failure to develop or obtain sales, marketing
and distribution resources and expertise or to otherwise manage its
growth; a loss of any of Vanda's key scientists or management
personnel; losses incurred from product liability claims made
against Vanda; a loss of rights to develop and commercialize
Vanda's products under its license and sublicense agreements and
other factors that are described in the "Risk Factors" section
(Part I, Item 1A) of Vanda's annual report on Form 10-K/A for the
fiscal year ended December 31, 2008 (File No. 001-34186). In
addition to the risks described above and in Part I, Item 1A of
Vanda's annual report on Form 10-K/A, other unknown or
unpredictable factors also could affect Vanda's results. There can
be no assurance that the actual results or developments anticipated
by Vanda will be realized or, even if substantially realized, that
they will have the expected consequences to, or effects on, Vanda.
Therefore, no assurance can be given that the outcomes stated in
such forward-looking statements and estimates will be achieved. All
written and verbal forward-looking statements attributable to Vanda
or any person acting on its behalf are expressly qualified in their
entirety by the cautionary statements contained or referred to
herein. Vanda cautions investors not to rely too heavily on the
forward-looking statements Vanda makes or that are made on its
behalf. The information in this release is provided only as of the
date of this release, and Vanda undertakes no obligation, and
specifically declines any obligation, to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise. VANDA PHARMACEUTICALS INC.
(A Development Stage Enterprise) CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS (Unaudited) Three Months Ended ------------------
March 31, March 31, 2009 2008 ---- ---- Revenue $- $- ----- -----
Operating expenses: Research and development 2,333,344 11,102,665
General and administrative 4,224,031 8,959,214 --------- ---------
Total operating expenses 6,557,375 20,061,879 --------- ----------
Loss from operations (6,557,375) (20,061,879) Interest income
53,387 865,750 ------ ------- Total other income, net 53,387
865,750 ------ ------- Net loss $(6,503,988) $(19,196,129)
=========== ============ Basic and diluted net loss per share
attributable to common stockholders $(0.24) $(0.72) ====== ======
Shares used in calculation of basic and diluted net loss per share
attributable to common stockholders 26,653,478 26,648,344
========== ========== VANDA PHARMACEUTICALS INC. (A Development
Stage Enterprise) CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
March 31, December 31, 2009 2008 ----------- ----------- ASSETS
Current assets: Cash and cash equivalents $33,833,465 $39,079,304
Marketable securities 8,810,919 7,378,798 Prepaid expenses,
deposits and other current assets 1,118,672 1,287,400 ---------
--------- Total current assets 43,763,056 47,745,502 Property and
equipment, net 1,635,316 1,758,111 Restricted cash 430,230 430,230
------- ------- Total assets $45,828,602 $49,933,843 ===========
=========== LIABILITIES AND STOCKHOLDERS' EQUITY Current
liabilities: Accounts payable $1,415,384 $512,382 Accrued expenses
2,065,219 2,898,417 --------- --------- Total current liabilities
3,480,603 3,410,799 Long-term liabilities: Deferred rent 503,791
502,770 ------- ------- Total liabilities 3,984,394 3,913,569
--------- --------- Stockholders' equity: Common stock 26,653
26,653 Additional paid-in capital 273,296,804 270,988,157
Accumulated other comprehensive loss (754) (20,029) Deficit
accumulated during the development stage (231,478,495)
(224,974,507) ------------ ------------ Total stockholders' equity
41,844,208 46,020,274 ---------- ---------- Total liabilities and
----------- ----------- stockholders' equity $45,828,602
$49,933,843 =========== =========== VANDA PHARMACEUTICALS INC. (A
Development Stage Enterprise) CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS (Unaudited) Three Months Ended ------------------ March
31, March 31, 2009 2008 ---- ---- Cash flows from operating
activities: Net loss $(6,503,988) $(19,196,129) Adjustments to
reconcile net income to net cash used in operating activities:
Depreciation and amortization 122,795 122,629 Stock-based
compensation 2,308,647 5,105,714 Loss on disposal of assets - 610
Amortization of net discounts on short-term investments 38,263
(162,519) Changes in assets and liabilities: Prepaid expenses and
other current assets 168,728 606,421 Accounts payable 903,002
(1,355,101) Accrued expenses (833,198) (1,299,209) Other
liabilities 1,021 68,365 ----- ------ Net cash used in operating
activities (3,794,730) (16,109,219) ---------- ----------- Cash
flows from investing activities: Purchases of property and
equipment - (186,442) Purchases of marketable securities
(5,077,656) (1,485,150) Proceeds from sales of marketable
securities 126,547 2,790,026 Maturities of marketable securities
3,500,000 29,060,000 --------- ---------- Net cash provided by
(used in) investing activities (1,451,109) 30,178,434 ----------
---------- Cash flows from financing activities: Net cash provided
by ----- ------ financing activities - - ----- ------ Effect of
foreign currency translation - 16,745 ----- ------ Net change in
cash and cash equivalents (5,245,839) 14,085,960 Cash and cash
equivalents, beginning of period 39,079,304 41,929,533 ----------
---------- Cash and cash equivalents, end of period $33,833,465
$56,015,493 =========== =========== DATASOURCE: Vanda
Pharmaceuticals Inc. CONTACT: CONTACT: Stephanie R. Irish, Acting
Chief Financial Officer of Vanda Pharmaceuticals Inc.,
+1-240-599-4500, Web Site: http://www.vandapharma.com/
Copyright
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024